The manufacturer of the famous Wegovy drug for chronic weight management in adults and adolescents, Novo Nordisk, received approval from the FDA (Food and Drug Administration) of the US government to launch the first-ever GLP-1 (glucagon-like peptide-1) pills for orally managing obesity.
Previously, GLP-1 treatments were in the form of injectable-only options. This new drug has significant implications for the health market in the US. With the option of an oral medication for obesity, Novo Nordisk is opening the treatment access to a wider range of patients.
Novo Nordisk Drug Launch Set for January 2026
According to Novo Nordisk, the drug will be launched in early 2026 for public access. With a savings offer of $149/month, the drug will be made available via select telehealth providers. This is in early January of 2026. According to the drug maker, the starting dose will be 1.5 milligrams.
This price is the same, according to President Donald Trump’s direct-to-consumer website. Industry experts are noting that this could be a result of the deal Novo Nordisk was able to make with the Trump administration. The direct-to-consumer initiative by Trump had seen a lot of resistance from the Democrats, as they deem this initiative against the famed Obamacare. The website for the direct-to-consumer initiative, TrumpRx, is also set to launch in January.
As of now, Novo Nordisk has not disclosed further details about the higher doses of the drug. According to the company, the details regarding the said matter will be disclosed upon the launch scheduled in January.
Novo Nordisk Shares Soar 10% After FDA Approval
Following the news regarding the new drug, Novo Nordisk’s shares rose by 10% on Monday’s extended trading. This was a much-needed spike as Novo Nordisk’s 2025 performance was not exactly the best among pharmaceutical stocks. The approval that came late afternoon on 22nd December, 2025, had a great impact on the stock price. Novo Nordisk was trading flat at $48.10, jumped as high as $53.01 post the FDA announcement.
The oral obesity market is a highly competitive arena among pharmaceutical stocks, and gaining the first-mover edge served well for Novo Nordisk as its immediate rival, Eli Lilly, saw its stock dip roughly 1% in overnight trading.
There were several reasons that caused such a market movement, according to industry experts. Convenience is being identified as the major supporting factor that has pushed Novo Nordisk ahead of the competition. What was previously only available as a weekly injection can now be taken as a daily oral dose. This convenience is sure to gain a lot of customers. The oral consumption will also attract a lot of new consumers who are needle-hesitant.
Novo Nordisk additionally gains a lot of manufacturing advantages as it transitions from the injection-only dose to an oral dose. Oral medications are cheaper to manufacture and distribute in comparison with injection medications.
Analysts Forecast GLP-1 Drugs to Capture 24% Market Share
The latest developments in the pharmaceutical industry have sparked debates on Wall Street. The general view that is dominating Wall Street is that pills come with a distinct advantage. This is what gives Novo Nordisk the first-mover edge. While Novo Nordisk’s Wegovy injection drug for treating obesity came second to Eli Lilly’s Zepbound in 2025, the move towards an oral medication gave Novo Nordisk the distinct advantage.
The competition is set to intensify as Eli Lilly is also in the race to manufacture an oral medication for obesity. The significance of this race is further emphasized by Goldman Sachs, whose analysts have predicted that the weight loss drugs will occupy 24% of the market share for weight loss treatments, amounting to nearly 22 billion US dollars by August 2026.
The race to dominate the market gains even more significance as during the shortage of GLP-1 category drugs in 2024, patients had shifted to low-quality, compounded copycats of the medication. The direct-to-consumer initiative also gains special mention as it can bring the price of Novo Nordisk’s latest drug in line with that of these copycat drugs.
